SLC17A2 inhibitors are a class of chemical compounds that specifically target and inhibit the function of the SLC17A2 protein, a member of the solute carrier family. SLC17A2 is part of the larger SLC17 family, which is known for its role in transporting organic anions, including neurotransmitters and other small molecules, across cellular membranes. The inhibition of SLC17A2 can disrupt the transport processes it mediates, offering researchers a powerful tool to study the protein's function and its broader impact on cellular activities. By selectively inhibiting SLC17A2, scientists can explore how this transporter influences the distribution and concentration of specific anions within cells, and how these changes affect cellular metabolism and signaling.
The use of SLC17A2 inhibitors in research is particularly valuable for dissecting the role of this transporter in various biological systems. By blocking SLC17A2 activity, researchers can observe the resulting alterations in cellular processes, such as changes in ion gradients, neurotransmitter release, and intracellular signaling pathways. These studies help to elucidate the specific substrates transported by SLC17A2 and the physiological contexts in which this transporter is most active. Additionally, SLC17A2 inhibitors can be used to explore the regulatory mechanisms that control the expression and activity of this protein, providing insights into how cells maintain homeostasis in response to environmental and intracellular cues. Through these investigations, SLC17A2 inhibitors contribute to a deeper understanding of membrane transport mechanisms and the complex interplay between transport proteins and cellular function.
VER TAMBIÉN ....
Items 1 to 10 of 19 total
Mostrar:
| Nombre del producto | NÚMERO DE CAS # | Número de catálogo | Cantidad | Precio | MENCIONES | Clasificación |
|---|---|---|---|---|---|---|
D(−)-2-Amino-5-phosphonovaleric acid (D-AP5) | 79055-68-8 | sc-200434 | 5 mg | ¥1072.00 | 2 | |
Como antagonista del receptor NMDA, el AP5 puede influir indirectamente en la señalización y liberación de glutamato. | ||||||
6-Cyano-7-nitroquinoxaline-2,3-dione | 115066-14-3 | sc-505104 | 10 mg | ¥2302.00 | 2 | |
CNQX es un potente antagonista de los receptores AMPA, que influye indirectamente en la señalización y liberación de glutamato. | ||||||
Kynurenic acid | 492-27-3 | sc-202683 sc-202683A sc-202683B | 250 mg 1 g 5 g | ¥282.00 ¥632.00 ¥1523.00 | 6 | |
Se trata de un antagonista de amplio espectro de los receptores de aminoácidos excitatorios, por lo que reduce la señalización del glutamato. | ||||||
Riluzole | 1744-22-5 | sc-201081 sc-201081A sc-201081B sc-201081C | 20 mg 100 mg 1 g 25 g | ¥226.00 ¥2132.00 ¥2358.00 ¥3509.00 | 1 | |
El riluzol inhibe la liberación de glutamato, influyendo indirectamente en la función del SLC17A7. | ||||||
Ethosuximide | 77-67-8 | sc-211431 | 1 g | ¥3385.00 | ||
Este compuesto reduce la actividad de los canales de calcio de tipo T, lo que puede influir indirectamente en la liberación de glutamato. | ||||||
Lamotrigine | 84057-84-1 | sc-201079 sc-201079A | 10 mg 50 mg | ¥1331.00 ¥5370.00 | 1 | |
La lamotrigina inhibe los canales de sodio sensibles al voltaje, lo que provoca una disminución de la liberación de glutamato. | ||||||
Topiramate | 97240-79-4 | sc-204350 sc-204350A | 10 mg 50 mg | ¥1185.00 ¥4084.00 | ||
Modula las corrientes provocadas por GABA, lo que influye indirectamente en la liberación de glutamato. | ||||||
Felbamate | 25451-15-4 | sc-203579 sc-203579A | 10 mg 50 mg | ¥1139.00 ¥4208.00 | ||
El felbamato actúa como antagonista de los receptores NMDA, afectando indirectamente a la señalización y liberación de glutamato. | ||||||
FCCP | 370-86-5 | sc-203578 sc-203578A | 10 mg 50 mg | ¥1038.00 ¥3926.00 | 46 | |
Un protonóforo, altera los gradientes de protones, influyendo potencialmente en la función del SLC17A. | ||||||
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | ¥350.00 | 3 | |
Un antiinflamatorio no esteroideo, puede afectar indirectamente a los canales y transportadores iónicos como el SLC17A. | ||||||